Homepage Top Section2

This programme is designed to expedite the development and review of new therapies targeting serious or life-threatening conditions by demonstrating the potential to address unmet medical needs. A

This application aims to provide a new treatment option for adult patients who have priorly treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is epidermal

Sabirnetug is a humanised monoclonal antibody that has shown selective target engagement with toxic soluble amyloid beta (Aβ) oligomers in patients with AD. The partnership between Acumen and

An injectable treatment, DESFERAL is intended to treat iron overload conditions, often arising from blood transfusions in patients with beta-thalassaemia and sickle-cell anaemia. Beta-thalassaemia and sickle cell anaemia

The recommended dosage for adults is an initial 10mg/kg of teprotumumab, followed by 20mg/kg for subsequent doses every three weeks, totalling eight infusions. TEPEZZA was granted orphan drug

EO-3021 is designed for GC/GEJ patients whose tumours express Claudin 18.2 and have progressed following prior therapy. The FTD status aims to accelerate the development and review of

The treatment targets those with folate receptor alpha (FRα)-positive, platinum-resistant, and high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three treatment

This topical therapy is aimed at treating moderate to severe skin rash. Azitra CEO Francisco Salva said: “Many cancer patients receive EGFR inhibitors, which often have significant side

This designation will offer potential benefits such as tax credits and fee waivers to facilitate the drug’s development. The ODD status is intended for potential treatments for diseases